The Takeda 3001 clinical trial is for people with a diagnosis of Alpha-1 Antitrypsin Deficiency and METAVIR Stage F2-F4 liver fibrosis. It involves an injection of a medication, fazirsiran, administered roughly every 12 weeks for 2 years.
To be eligible for the trial, participants must meet the following criteria:
- Must be between the ages of 18 - 75 years
- Have the PiZZ genotype of the Alpha-1 Antitrypsin Deficiency ONLY (PiMZ or PiSZ are not eligible)
- A METAVIR Stage F2-F4 biopsy within 1 year (or at screening).
- No history of medium-large varices, liver decomposition, HCC or other chronic liver diseases
- No smoking throughout the trial
To learn more please email: kianakhbari@arizona.edu